Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Nordics has been experiencing a steady growth in recent years.
Customer preferences: Patients in the Nordics have shown a preference for biologic drugs as they are perceived to be more effective in treating autoimmune diseases. This has led to an increase in demand for biologic immunosuppressants. Additionally, there is a growing trend towards personalized medicine, where treatments are tailored to the individual patient. This has led to an increase in the use of genetic testing to determine the most effective treatment for each patient.
Trends in the market: The market for immunosuppressants in the Nordics is being driven by an increase in the prevalence of autoimmune diseases. This is due to factors such as an aging population, increased awareness and diagnosis of autoimmune diseases, and environmental factors. As a result, there is a growing demand for immunosuppressant drugs to treat these conditions. Additionally, there is a trend towards the development of new biologic drugs, which are more effective and have fewer side effects than traditional immunosuppressants.
Local special circumstances: The healthcare systems in the Nordics are publicly funded, which means that the government has a significant role in determining which drugs are available to patients. This can lead to delays in the approval and reimbursement of new drugs. However, the Nordics are known for their high standards of healthcare, and patients have access to some of the most advanced treatments in the world.
Underlying macroeconomic factors: The Nordics have a strong and stable economy, which has allowed for investment in research and development of new drugs. Additionally, there is a high level of education and innovation in the region, which has led to the development of new and innovative treatments. However, the high cost of these drugs can be a barrier to access for some patients, and there is ongoing debate about the balance between innovation and affordability in the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
